196 related articles for article (PubMed ID: 20142023)
1. Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension.
Blalock SE; Matulevicius S; Mitchell LC; Reimold S; Warner J; Peshock R; Torres F; Chin KM
J Card Fail; 2010 Feb; 16(2):121-7. PubMed ID: 20142023
[TBL] [Abstract][Full Text] [Related]
2. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.
Galiè N; Olschewski H; Oudiz RJ; Torres F; Frost A; Ghofrani HA; Badesch DB; McGoon MD; McLaughlin VV; Roecker EB; Gerber MJ; Dufton C; Wiens BL; Rubin LJ;
Circulation; 2008 Jun; 117(23):3010-9. PubMed ID: 18506008
[TBL] [Abstract][Full Text] [Related]
3. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension.
Oudiz RJ; Galiè N; Olschewski H; Torres F; Frost A; Ghofrani HA; Badesch DB; McGoon MD; McLaughlin VV; Roecker EB; Harrison BC; Despain D; Dufton C; Rubin LJ;
J Am Coll Cardiol; 2009 Nov; 54(21):1971-81. PubMed ID: 19909879
[TBL] [Abstract][Full Text] [Related]
4. Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan.
Shapiro S; Pollock DM; Gillies H; Henig N; Allard M; Blair C; Anglen C; Kohan DE
Am J Cardiol; 2012 Nov; 110(9):1373-7. PubMed ID: 22858181
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study.
Huo Y; Jing ZC; Zeng XF; Liu JM; Yu ZX; Zhang GC; Li Y; Wang Y; Ji QS; Zhu P; Wu BX; Zheng Y; Wang PP; Li J
BMC Cardiovasc Disord; 2016 Oct; 16(1):201. PubMed ID: 27770771
[TBL] [Abstract][Full Text] [Related]
6. Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial.
Fischer A; Denton CP; Matucci-Cerinic M; Gillies H; Blair C; Tislow J; Nathan SD
Respir Med; 2016 Aug; 117():254-63. PubMed ID: 27492539
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and tolerability of ambrisentan treatment for pediatric patients with pulmonary arterial hypertension: An open-label extension study.
Ivy D; Beghetti M; Juaneda-Simian E; Ravindranath R; Lukas MA; Machlitt-Northen S; Scott N; Narita J; Berger RMF
Eur J Pediatr; 2024 May; 183(5):2141-2153. PubMed ID: 38366267
[TBL] [Abstract][Full Text] [Related]
8. Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial.
Preston IR; Burger CD; Bartolome S; Safdar Z; Krowka M; Sood N; Ford HJ; Battarjee WF; Chakinala MM; Gomberg-Maitland M; Hill NS
J Heart Lung Transplant; 2020 May; 39(5):464-472. PubMed ID: 32008947
[TBL] [Abstract][Full Text] [Related]
9. Ambrisentan therapy for pulmonary arterial hypertension.
Galié N; Badesch D; Oudiz R; Simonneau G; McGoon MD; Keogh AM; Frost AE; Zwicke D; Naeije R; Shapiro S; Olschewski H; Rubin LJ
J Am Coll Cardiol; 2005 Aug; 46(3):529-35. PubMed ID: 16053970
[TBL] [Abstract][Full Text] [Related]
10. Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study).
Pan Z; Marra AM; Benjamin N; Eichstaedt CA; Blank N; Bossone E; Cittadini A; Coghlan G; Denton CP; Distler O; Egenlauf B; Fischer C; Harutyunova S; Xanthouli P; Lorenz HM; Grünig E
Arthritis Res Ther; 2019 Oct; 21(1):217. PubMed ID: 31655622
[TBL] [Abstract][Full Text] [Related]
11. Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension.
Klinger JR; Oudiz RJ; Spence R; Despain D; Dufton C
Am J Cardiol; 2011 Jul; 108(2):302-7. PubMed ID: 21545989
[TBL] [Abstract][Full Text] [Related]
12. Does treatment response to ambrisentan vary by pulmonary arterial hypertension severity? Implications for clinicians and for the design of future clinical trials.
Chin KM; Bartolome S; Miller K; Blair C; Gillies H; Torres F
Int J Clin Pract; 2014 May; 68(5):568-77. PubMed ID: 24499136
[TBL] [Abstract][Full Text] [Related]
13. Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study.
Hoeper MM; McLaughlin VV; Barberá JA; Frost AE; Ghofrani HA; Peacock AJ; Simonneau G; Rosenkranz S; Oudiz RJ; White RJ; Miller KL; Langley J; Harris JHN; Blair C; Rubin LJ; Vachiery JL
Lancet Respir Med; 2016 Nov; 4(11):894-901. PubMed ID: 27745818
[TBL] [Abstract][Full Text] [Related]
14. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension.
Badesch DB; Feldman J; Keogh A; Mathier MA; Oudiz RJ; Shapiro S; Farber HW; McGoon M; Frost A; Allard M; Despain D; Dufton C; Rubin LJ;
Cardiovasc Ther; 2012 Apr; 30(2):93-9. PubMed ID: 21884013
[TBL] [Abstract][Full Text] [Related]
15. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.
Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; McLaughlin VV; Peacock AJ; Simonneau G; Vachiery JL; Grünig E; Oudiz RJ; Vonk-Noordegraaf A; White RJ; Blair C; Gillies H; Miller KL; Harris JH; Langley J; Rubin LJ;
N Engl J Med; 2015 Aug; 373(9):834-44. PubMed ID: 26308684
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials).
Maron BA; Waxman AB; Opotowsky AR; Gillies H; Blair C; Aghamohammadzadeh R; Loscalzo J; Leopold JA
Am J Cardiol; 2013 Sep; 112(5):720-5. PubMed ID: 23751938
[TBL] [Abstract][Full Text] [Related]
17. Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1).
Shapiro S; Torres F; Feldman J; Keogh A; Allard M; Blair C; Gillies H; Tislow J; Oudiz RJ
Respir Med; 2017 May; 126():84-92. PubMed ID: 28427554
[TBL] [Abstract][Full Text] [Related]
18. Ambrisentan.
Croxtall JD; Keam SJ
Drugs; 2008; 68(15):2195-204. PubMed ID: 18840007
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension.
Cartin-Ceba R; Swanson K; Iyer V; Wiesner RH; Krowka MJ
Chest; 2011 Jan; 139(1):109-14. PubMed ID: 20705798
[TBL] [Abstract][Full Text] [Related]
20. Ambrisentan for the management of pulmonary arterial hypertension.
Cheng JW
Clin Ther; 2008 May; 30(5):825-33. PubMed ID: 18555930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
